NX 303
Alternative Names: Oxybutynin transdermal - NovavaxLatest Information Update: 02 Oct 2021
At a glance
- Originator Novavax
- Class Alkynes; Antispasmodics; Carbocyclic acids; Cyclohexanes; Diethylamines; Esters; Mandelic acids; Skin disorder therapies; Small molecules
- Mechanism of Action Cholinergic receptor antagonists; Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bladder dysfunction; Urination disorders
Most Recent Events
- 13 Jun 2005 Preclinical trials in Bladder dysfunction in USA (Transdermal)
- 13 Jun 2005 Preclinical trials in Urination disorders in USA (Transdermal)